Invex Therapeutics Ltd reported earnings results for the full year ended June 30, 2023. For the full year, the company reported net loss was AUD 7.75 million compared to AUD 3.95 million a year ago. Basic loss per share from continuing operations was AUD 0.1031 compared to AUD 0.0526 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.066 AUD | 0.00% | +1.54% | -18.52% |
Mar. 20 | Australia's Tax Agency Publishes Ruling on Invex Therapeutics' Capital Return | MT |
Feb. 16 | Invex Therapeutics Narrows Fiscal H1 Loss on Lower R&D Expenses | MT |
1st Jan change | Capi. | |
---|---|---|
-18.52% | 3.36M | |
+23.50% | 47.07B | |
+47.58% | 42.06B | |
-5.16% | 39.98B | |
+36.37% | 33.02B | |
-7.79% | 27.9B | |
+18.06% | 27.63B | |
+47.29% | 14.37B | |
+41.91% | 13.45B | |
-1.02% | 12.03B |
- Stock Market
- Equities
- IXC Stock
- News Invex Therapeutics Ltd
- Invex Therapeutics Ltd Reports Earnings Results for the Full Year Ended June 30, 2023